{
  "contract_id": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement_cleaned",
  "original_file": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement_cleaned.txt",
  "chunk_size": 1000,
  "chunk_overlap": 200,
  "total_chunks": 5,
  "chunks": [
    "Exhibit 10.1 Certain information identified by bracketed asterisks ([ * * * ]) has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed. EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement\") is entered into as of June 12, 2019 (the \"Execution Date\") by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park, Illinois, USA (\"ETON\"), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ 08854 (\"Aucta\")",
    ". RECITALS WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products; WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined); WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms and conditions set forth herein; WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under the terms and conditions set forth herein; and WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective Date (later defined) occurs",
    ". NOW, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending to be legally bound, hereby agree as follows: 1. DEFINITIONS. For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below: 1.1 \"Affiliates\" means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is controlled by or is under common control with such entity. For the purposes of this definition, \"control\" means the ownership of at least 50% of the voting share capital of an entity or any other comparable equity or ownership interest. 1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
    "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
    "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019\nSource: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019"
  ]
}